The design and molecular modeling of CNS drugs

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 4, 1999, Pages 286-292

  George, Ashley ^a  

^a NONE   (United Kingdom)

Author keywords

Bioavailability; Blood brain barrier; CNS drugs; Metabolism; Modeling

Indexed keywords

ACTIVE TRANSPORT; ARTICLE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DIFFUSION; DRUG DESIGN; DRUG METABOLISM; DRUG PENETRATION; MOLECULAR MODEL;

EID: 0032804804     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. Pardridge WM: CNS drug design based on principles of blood-brain barrier transport. J Neurochem (1998) 70(5):1781-1792.
2. •• A comprehensive review of fundamental pharmacological methods forBBB transport.
3. U'pinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 23(1 -3):3-25.
4. •• Review that sets the field of modeling towards complex drug properties such as bioavailability instead of drug/protein interactions.
5. Merrill JE, Benveniste EN: Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci (1996) 19:331-338.
6. Lee MX, Cleveland DW: Neuronal intermediate filaments. Annu Rev Neurosci (WS6) 19:187-217.
7. van de Vrie W, Marquet RL, Stoter G, De Bruijn EA, Eggenmont AM: In vivo model systems In P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sd (1998) 35(1 ):1 -57.
8. Cordon-Cardo C, O'Brien JP, Caslas D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. P roc Näil Acad Sei USA (1989) 86:695-698.
9. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J: Pglycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sei (1992) 51:1427-1437.
10. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem (1993) 62:385-427.
11. Ferry DR, Traunecker H, Kerr DJ: Clinical trails of Pglycoprotein reversal in solid tumours. EurJ Cancer (1996) 32A: 1070-1081.
12. Ford JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. EurJ Cancer (1996) 32A:991-1001.
13. Begley DJ: The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm P/)a/maco/(1996) 48(2): 136-146.
14. • Review of aspects of drug delivery.
15. van Bree JB, de Boer AG, Danhof M, Ginsel LA, Breimer DD: Characterization of an in-vitro blood-brain barrier effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther (1988)247:1233-1239.
16. Leo AJ: The future of log P calculation. Methods Princ Med Chem (Lipophilicity in Drug Action and Toxicology) (1996) 4:157-172.
17. Takacs-Novak K: Computerized logP prediction using fragment methods. Ada Pharm Hung (1998) 68(1 ):39-48.
18. Leo AJ: Calculating log P octanol - no missing fragments. 217th ACS National Meeting, Anaheim, CA, 21-25 March (1999):COMP-105.
19. Yue S-Y, Tomkinson N, Roberts E: Using molecular hologram to predict n-octanol/water partition coefficient. 217th ACS National Meeting, Anaheim, CA, 21-25 March (1999):COMP-220.
20. Hurst T: HQSAR - A highly predictive QSAR technique based on molecular holograms. 213th ACS National Meeting, San Francisco, CA, 13-17 April (1997):CINF-019.
21. Heritage TW, Hurst T: HQSAR - A highly predictive QSAR technique based on molecular holograms. 214th ACS National Meeting, Las Vegas, NV, 7-11 September (1997):COMP-080.
22. Gratton JA, Abraham MH, Bradbury MW, Chadha HS: Molecular factors influencing drug transfer across the blood-brain barrier. J Pharm Pharmacol (1997) 49(12): 1211 -1216.
23. Abraham MH, Chadha HS, Martins F, Mitchell RC, Bradbury MW, G ratton JA: Hydrogen bonding part 46: A review of the correlation and prediction of transport properties by an LFER method: Physicochemical properties, brain penetration and skin permeability. Pesticide Sei (1999) 55(1):78-88.
24. Clark DE: Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 217th ACS National Meeting, Anaheim, CA, 2125 March (1999):COMP-190.
25. Palm K, Artursson P, Luthman K: Experimental and theoretical predictions of intestinal drug absorption. In: ComputerAssisted Lead Finding and Optimization (Proceedings of the 11" European Symposium on Quantitative Structrure-Act'vity Relationship), van de Waterbeemd H, Testa B, Folkers G (Eds). Verlag Helvetica Chimica Acta, Basel (1997):279-289.
26. Palm K, Luthman K, Ungell A-L, Strandlund G, Beigi F, Lundahl P, Artursson P: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors. J Med Chem (1998) 41 (27):5382-5392.
27. • Good overview of PSA.
28. Palm K, Stenberg P, Luthman K, Artursson P: Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res (1997) 14(5):568-571.
29. van de Waterbeemd H, Camenisch G, Folkers G, Chrétien JR. Raevsky OA: Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Targeting (1998) 6(2):151-165.
30. Luco JM: Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J Chem Inf Comput Sc/(1999) 39(2):396-404.
31. Norinder U. Osterberg T, Artursson P: Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parameterization and PLS statistics. Eur J Pharm Sei (1999) 8(1 ):49-56.
32. Norinder U, Sjoeberg P, Oesterberg T: Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parameterization and PLS statistics. J Pharm Sei (1998) 87(8):952-959.
33. Sjoberg P: MolSurf - a generator of chemical descriptors for QSAR. In: Computer-Assisted Lead Finding and Optimization (Proceedings of the 11" European Symposium on Quantitative Structrure-Activity Relationship), van de Waterbeemd H, Testa B, Folkers G (Eds). Verlag Helvetica Chimica Acta, Basel (1997):83-92.
34. Lombardo F, Blake JF, Curatolo WJ: Computation of brainblood partitioning of organic solutes via free energy calculations. J Med Chem (1996) 39(24):4750-4755.
35. Anderson BD: Prodrugs for improved CNS delivery. Adv Drug Deliv Rev (1996) 19(2):171 -202.
36. •• Good review of the prodrug area and its application to the delivery of different compound classes.
37. Wade LA, Katzman R: Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J Neureichem (1975) 25(6):837-842.
38. Poll R, Porreca F, Szabo LZ, Bilsky EJ, Davis P, Abbruscato TJ, Davis TP, Horvath R, Yamamura HI, Hruby VJ: Glycopeptide enkephalin analogs produce analgesia in mice: Evidence for penetration of the blood-brain barrier. Proc Natl Acad Sei USA (1994) 91(15):7114-7118.
39. Bickel U, Schumacher OP, Kang Y-S, Voigt K: Poor permeability of morphine 3-glucuronide and morphine 6glucuronide through the blood-brain barrier In the rat. J PharmacolExp Ther(W96) 278(1):107-113.
40. Wu D, Kang Y-S, Bickel U, Pardridge WM: Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos (1997) 25(6):768-771.
41. • In conjunction with reference [34], details how simple molecular changes might not be suitable for using the active uptake systems.
42. Syed SK, Christopherson RI, Roufogalis BD: Reversal of vinblastine transport by chlorpromazine in membrane vesicles from multidrug-resistant human CCRF-CEM leukemia cells. Br J Cancer (1998) 78(3):321-327.
43. DiDiodato G, Sharom FJ: Interaction of combinations of drugs, chemosensitizers, and peptides with the Pglycoprotein multidrug transporter. Biochem Pharmacol (1997)53:1789-1797.
44. • Good overview of PgP pharmacology.
45. Huet S, Chapey C, Robert J: Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer Part A (1993) 29A(10):1377-1383.
46. Wadkins RM, Houghton PJ: The role of drug-lipid interactions in the biological activity of modulators of multi-drug resistance. Biochim Biophys Ada (1993) 1153(2):225-236.
47. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin //ives/(1998) 101(2):289-294.
48. Terasaki T, Hosoya Kl: The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev (1999) 36(2-3):195-209.
49. Wiese M, Pajeva IK: Molecular modelling study of the multidrug resistance modifiers cis- and trans-flupentixol. Pharmazie (1997) 52(9):679-685.
50. Etievant C, Schambel P, Guminski Y, Barret J-M, Imbert T, Hill BT: Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series. Anti Cancer Drug Des (1998) 13:317-336.
51. Dong M, Ladavière L, Penin F, Deléage G, Baggetto LG: Secondary structure of P-glycoprotein investigated by circular dichroism and amino acid sequence analysis. Biochim Biophys Acta Biomembr (1998) 1371:313-334.
52. Vasudevan S, Tsuruo T, Rose DR: Mode of binding of anti-Pglycoprotein antibody MRK-16 to its antigen. J Biol Chem (1998) 273(39):25413-25419.
53. Käst C, Gros P: Epitope insertion favors a six transmembrane domain model for the carboxy-terminal portion of the multidrug resistance-associated protein. Biochemistry (1998) 37:2305-2313.
54. Shapiro AB, Ung V: Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. EurJ Biochem (1997) 250:130-137.
55. Wang G, Pincheira R, Zhang J-T: Dissection of drugbinding-induced conformational changes in Pglycoprotein. EurJ Biochem (1998) 255:383-390.
56. Jones PM, George AM: A new structural model for Pglycoprotein. J Membrane S/o/(1998) 166:133-147.
57. •• The 3-D structural model of the PgP protein, detailing previous experimental work and the models derivation.
58. Labute P: QuaSAR-binary: a new method for the analysis of high throughput screening data. Network Sei (1998) 4(S):http-S/www.netsci.org/Science/Compchem/feature21.html.
59. Gao H, Williams C, Labute P, Bajorath J: Binary quantitative structure-activity relationship (QSAR) analysis of estrogen receptor ligands. J Chem Inf Comput Sei (1999) 39(1 ):164-168.
60. •• In association with reference [50], this work could prove very interesting in the future as a possible methodology to investigate datamining in crude HTS data.
61. Lemieux B, Aharoni A, Schena M: Overview of DNA chip technology. Mot Breed (1998) 4(4):277-289.
62. Jordan BR: Large-scale expression measurement by hybridization methods: From high-density membranes to 'DNA chips1. JBiochem (Tokyo) (1998) 124(2):251-258.
63. Neuwelt EA, Rapoport SI: Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. FedP/oc(1984) 43:214-219.
64. Bartus RT, Elliott P, Hayward N, Dean R, McEwen EL, Fisher SK: Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology (1996) 33(1 -3):270-278.
65. • Papers presented at KININ '95, 14th International Symposium on Bradykinin and Related Kinins, 1995.
66. Men!! JE, Murphy SP: Inflammatory events at the blood brain barrier; regulation of adhesion molecules, cytokines and chemokines by reactive nitrogen and oxygen species. Brain Behav Immun (1997) 11:245-263.
67. Moriguchi I, Hirono S, Nakagome I, Hirano H: Comparison of reliability of log P values for drugs calculated by several methods. Chem Pharm Bull (1994) 42(4):976-978.
68. Jansen G, Mauritz R, Drori S, Sprecher H, Kalhmann I, Bunni M, Priest DG, Noordhuis P, Schomagel JH, Pinedo HM, Peters GJ, Assaraf YG: A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem (1998) 273(46):30189-30198.
69. Marino AM, Chong S, Dando SA, Kripalani KJ, Bathala MS, Morrison RA: Distribution of the dipeptide transporter system along the gastrointestinal tract of rats based on absorption of a stable and specific probe, SQ-298S2. J P/7armSc;(1996) 85(3):282-286.
70. Borchardt RT: Profiling compounds for biopharmaceutical properties. 217th ACS National Meeting, Anaheim, CA, 21-25 March (1999):MEDI-160.
71. Hirono S, Nakagome I, Hirano H, Matsushita Y, Yoshii F. Moriguchi I: Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive leastsquares: Oral bioavailability. Biol Pharm Bull (1994) 17(2):306-309.
72. Moriguchi I, Hirono S: Fuzzy adaptive least squares and its use in quantitative structure-activity relationships. Pharmacochem L/or(1995) 23:275-297.
73. Topliss JG, Yoshida F: A QSAR model for drug human oral bioavailability. 217th ACS National Meeting, Anaheim, CA, 21-25 March (1999):COMP-092.
74. Takahashi Y, Miyashita Y, Abe H, Sasaki S: A new approach for ordered multicategorical classification using simplex technique. BunsekiKagaku (1984) 33(11):E487-E494.
75. Takahashi Y, Sasaki S-l, Tamaru M, Shimazaki I, Ito S, Kawada S, Suda Y: Application of the ORMUCS method to structureactivity studies on the fungicidal activity of mepronil derivatives. Quant Struct-Act Relat (1987) 6(1 ):17-21.
76. Martini LG, Avontuur P, Willson R, George A: Solubility parameter and oral absorption. Eur J Pharm Biopharm (1999) in press.
77. Fedors RF: Method for estimating both the solubility parameters and molar volumes of liquids. Polym Eng Sei (1974)14:147-154.
78. Vaughan CO: Solubility effects in product, package, penetration, and preservation. Cosmet Toiletries (1988) 103:47-69.
79. Hashiguchi T, Yasutake T. Manako T, Otagiri M: In vitro percutaneous absorption of prednisolone derivatives based on solubility parameter. IntJPham (1997) 158:11-18.
80. Bennett LJ, Miller KW: Application of regular solution theory to biomembranes. JMedC/?em(1974) 17:1124-1125.
81. Sloan KB, Koch SA, Siver KG, Flowers FP: Use of solubility parameters of drug and vehicle to predict flux through skin. J Invest Dermatol (1986) 87:244-252.
82. Mullins LJ: Some physical mechanisms in narcosis. Chem Rev (1954) 54:289-323.
83. Miller KW, Paton WOM, Smith EB: Site of action of general anaesthetics. Nature (1965) 206:574-577.
84. Shanker LS, Shore PA, Brodie BB, Hogben CA: Absorption of drugs from the stomach I; the rat. J Pharmacol Exp The r (1957a) 120:528-540.
85. Shanker LS, Shore PA, Brodie BB Hogben CA: Absorption of drugs from the stomach II; the human. J Pharmacol Exp T77er(1957a) 120:540-545.
86. Wessel MD, Jurs PC, Tolan JW, Muskai SM: Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sei (1998) 38(4):726-735.
87. Raevsky OA, Schaper K-J: Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs. EurJ MedChem (1998) 33(10):799-807.
88. Raevsky OA: Hydrogen bond strength estimation by means of the HYBOT program package. In: Computer-Assisted Lead Finding and Optimization (Proceedings of the 11" European Symposium on Quantitative Structrure-Activity Relationship), van de Waterbeemd H, Testa B, Folkers G (Eds). Verlag Helvetica Chimica Acta, Basel (1997):369-378.
89. Ajay A, Walters WP, Murcko MA: Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules? J Med Chem (1998) 41 (18):3314-3324.
90. • An interesting proposal for classification of drug-like and nondruglike molecules,
91. Anzali S, Gasteiger J, Holzgrabe U, Polanski J, Sadowski J, Teckentrup A, Wagener M: The use of self-organizing neural networks in drug design. Perspect Drug Discov Des (1998) 9/10/11(30 QSAR in drug design: Ljgand/protein interactions and molecular similarity):273-299.
92. Bauknecht H, Zell A, Bayer H, Levi P, Wagener M, Sadowski J, Gasteiger J: Locating biologically active compounds in medium-sized heterogeneous datasets by topological autocorrelation vectors: Dopamine and benzodiazepine agonists. J Chem Inf Comput Sc/(1996) 36(6):1205-1213.
93. Andrews PR, Lloyd EJ, Martin JL, Munro SLA: Central nervous system drug design. JMoiec Graphics (1986) 4(1):41-45.
94. Lloyd EJ, Andrews PR: A common structural model for central nervous system drugs and their receptor. J Med Chem (1986) 29:453-462.
95. • Along with reference [82], makes poignant reading in relation to the modem understanding of the activities of CNS drugs.
96. Stapleton G, Steel M, Richardson M, Mason JO, Rose KA, Moms RG, Lathe R: A novel cytochrome P450 expressed primarily in brain. J Biol Chem (1995) 270{50):29739-29745.
97. Hedlund E, Wyss A, Kainu T. Backlund M, Köhler C, PeltoHuikko M, Gustafsson J-A, Warner M: Cytochrome P4502D4 in the brain: Specific neuronal regulation by clozapine and toluene. Mol Pharmacol (1996) 50(2):342-350.
98. Hedlund E, Gustafsson J-A, Wamer M: Cytochrome P450 in the brain: 2B or not 2B. Trends Pharmacol Sei (1998) 19(3):82-85.
99. Lewis DF: Molecular modeling in drug metabolism: The cytochromes P450. Biomed Health Res (1998) 25(Drug Metabolism: Towards the Next Millennium):1-12.
100. • Good article for an overview of molecular modeling in drug metabolism.
101. Lewis DF, Lee-Robichaud P: Molecular modeling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal Structure. J Steroid Biochem Mol Biol (1998) 66(4):217-233.
102. Szklarz GD, Halpert JR: Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. /jfeSc;(1997) 61(26):2507-2520.
103. Dai R, Zhai S, Wei X, Pincus MR, Vestal RE, Friedman FK: Inhibition of human cytochrome P450 1A2 by flavones: A molecular modeling study. J Protein Chem (1998) 17(7):643650.
104. Dai R, Pincus MR, Friedman FK: Molecular modeling of cytochrome P450 2B1: mode of membrane insertion and substrate specificity. J Protein Chem (1998) 17(2):121-129.
105. Ekins S, Bravi G, Ring BJ, Giilespie TA, Gillespie JS, Vandenbranden M, Wrighton SA, Wikel JH: Threedimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther (1999) 288(1 ):21-29.
106. Lewis DF, Dickins M, Weaver RJ, Eddershaw PJ, Goldfarb PS, Tarbitt MH: Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: Rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica (1998) 28(3):235-268.
107. Arnold GE, Omstein RL: Molecular dynamics study of timecorrelated protein domain motions and molecular flexibility: Cytochrome P450BM-3. Biophys J (1997) 73(3):1147-1159.
108. de Groot MJ, Bijloo GJ, van Acker FA, Fonseca Guerra C, Snijders JG, Vermeulen NP: Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica (1997) 27(4):357-368.